Content Type: Article

  • Information Blocking Considerations for Health Systems Offering EHR System Access to Community Physicians and Facilitating Health Information Exchange

    Information Blocking Considerations for Health Systems Offering EHR System Access to Community Physicians and Facilitating Health Information Exchange

    CLIENT ALERT / INFORMATION BLOCKING / INTEROPERABILITY

    Information Blocking Considerations for Health Systems Offering EHR System Access to Community Physicians and Facilitating Health Information Exchange

    October 9, 2020

    Read time: 3 min

    Key takeaways
    Overview

    On September 17, 2020, the Office of Management and Budget received an Interim Final Rule for review from the Office of the National Coordinator for Health IT (ONC) entitled “Information Blocking and the ONC Health IT Certification Program: Extension of Compliance Dates and Timeframes in Response to the COVID-19 Public Health Emergency.” While the title suggests that health care providers and other regulated actors may have more time to come into compliance with ONC’s May 2020 information blocking final rule, details about potential delays remain scarce and health care providers would be well served to continue apace with compliance efforts, even if the original November 2, 2020 information blocking compliance date ultimately shifts.

    This is particularly true for hospitals and health systems that might also function in the capacity of a health information technology (IT) developer of certified health IT (Certified Health IT Developer) or health information network or health information exchange (HIN/HIE), because Certified Health IT Developers and HIN/HIEs face potential civil monetary penalties (CMPs) from the HHS Office of Inspector General (OIG)—as opposed to the yet undefined “appropriate disincentives” health care providers face. OIG is currently engaged in its own rulemaking to finalize regulations implementing its information blocking CMP authorities. In its proposed rule, OIG stated that it would not enforce CMPs for violations of the information blocking regulations that occur after November 2, 2020, but before OIG finalizes the CMPs. It is not clear how, if at all, any change to the ONC’s information blocking compliance date would impact the timing of OIG’s final rule (which is not yet at OMB for review) and, ultimately, timing of enforcement actions. Given such uncertainty, continued effort to identify and address areas of potential non-compliance with ONC’s final rule is advisable, particularly for actors that face potential CMPs of up to $1M per violation. For more information on the OIG proposed rule, see our On the Subject.

    To help health care providers that might also function as Certified Health IT Developers or HIN/HIEs identify potential areas of consideration and focus, we have developed the below resources. Please reach out to your McDermott lawyer or one of the contacts listed here to discuss your information blocking preparations.

    Additional Resources

    October 13 Webinar with The Chartis Group | APIs and Information Blocking: What Providers Need to Know
    REGISTER

    Visit McDermott’s Regulatory Sprint to Coordinated Care Resource page and subscribe for additional insights.

    In depth
    Authors

    James A. Cannatti III

    Partner

    Washington, DC

    Daniel F. Gottlieb

    Partner

    Chicago

    More insights

  • NYSE Further Extends Waiver of Parts of ‘Related Party’ and ‘20%’ Stockholder Approval Rules

    NYSE Further Extends Waiver of Parts of ‘Related Party’ and ‘20%’ Stockholder Approval Rules

    ARTICLE / CLIENT ALERT

    NYSE Further Extends Waiver of Parts of ‘Related Party’ and ‘20%’ Stockholder Approval Rules

    October 9, 2020

    Read time: 5 min

    Key takeaways
    Overview

    Recognizing that companies need quick access to capital due to the unprecedented disruption caused by COVID-19 and to mitigate against the NYSE stockholder approval rules presenting a hurdle to raising capital, the NYSE and the SEC approved the temporary waiver (“NYSE Waiver”) of certain NYSE stockholder approval rules set forth in Section 312.03 of the NYSE Listed Company Manual (“NYSE Manual”). The NYSE Waiver was last set to expire on Sept. 30, 2020, but, effective Sept. 28, 2020, has been extended through Dec. 31, 2020.[1] The relevant NYSE rules require a listed company to obtain stockholder approval before it issues 1% (or, in certain circumstances, 5%) of its outstanding shares of common stock or voting power pre-issuance to certain Related Parties[2] and before issuing in excess of 20% of its outstanding shares of common stock or voting power pre-issuance at a discount to the “NYSE Minimum Price.”[3]

    As described in more detail in our May 11, 2020 Alert, Nasdaq also adopted certain exceptions from its stockholder approval rules in response to the COVID-19 pandemic in Nasdaq Marketplace Rule 5636T, which expired on June 30, 2020 and has not been further extended. Both exchanges continue to provide an exception from their respective stockholder approval requirements where the delay caused by obtaining stockholder approval would “seriously jeopardize the financial viability of the company.”[4]

    Rule 312.03(b) — The Related Party Stockholder Approval Rule

    Rule 312.03(b) of the NYSE Manual generally requires a company to obtain stockholder approval for any issuance to a Related Party or to an affiliate of a Related Party if the number of shares of common stock to be issued or issuable exceeds 1% of the shares of common stock or voting power outstanding before the issuance. However, stockholder approval is not required for such issuances to substantial security holders that are not also a director or an officer if: (i) the price is equal to or greater than the NYSE Minimum Price; and (ii) the issuance does not exceed 5% of the shares of common stock or voting power before the issuance.

    The NYSE Waiver significantly relaxes the shareholder approval requirements under Rule 312.03(b) and facilitates capital raises with substantial security holders. Under the NYSE Waiver a company may issue stock to a Related Party regardless of amount to the extent the transaction satisfies the following conditions:

    • The transaction involves the sale of the company’s securities for cash.
    • The transaction satisfies the NYSE Minimum Price requirement.
    • The transaction must be reviewed and approved by the company’s audit committee or a comparable committee comprised solely of independent directors.
    • The proceeds of the transaction will not be used to fund an acquisition of stock or assets of another company where such person has a direct or indirect interest in the company or assets to be acquired or in the consideration to be paid for such acquisition in circumstances where shareholder approval would be required under Nasdaq Marketplace Rule 5635(a).

    Rule 312.03(c) — The 20% Stockholder Approval Rule

    Section 312.03(c) of the NYSE Manual requires shareholder approval of any transaction relating to 20% or more of the company’s outstanding common stock or voting power outstanding before such issuance other than:

    1. A public offering for cash; or
    2. Transactions involving a cash sale of the company’s securities that comply with the NYSE Minimum Price requirement and also constitutes a “bona fide private financing,” defined in Rule 312.04(g) of the NYSE Manual as meeting the following criteria:
      • A registered broker-dealer purchases the securities from the company with a view to the private sale of such securities to one or more purchasers; or
      • The company sells the securities to multiple purchasers, and no one such purchaser, or group of related purchasers, acquires, or has the right to acquire upon exercise or conversion of the securities, more than 5% of the shares of the company’s common stock or voting power before the sale.

    With respect to the “bona fide private financing” requirement, the NYSE Waiver does away with the 5% limitation to an individual investor and permits companies to undertake a bona fide private financing to a single purchaser.

    Any transaction that qualifies for the NYSE Waiver will still be subject to shareholder approval if required under any other applicable rule, including the equity compensation and change of control requirements.

    Authored by Eleazer Klein, Adriana Schwartz and Clara Zylberg.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] SEC Release No. 34-90020; File No. SR-NYSE-2020-79, available here.

    [2] A “Related Party” is defined under NYSE Marketplace Rules as a director, officer or a substantial security holder (a holder of 5% or more of the company’s common stock).

    [3] The “NYSE Minimum Price” is the lower of: (i) the official closing price on the NYSE as reported on the consolidated tape immediately preceding the signing of a binding agreement to issue the securities (“NYSE Official Closing Price”); and (ii) the average of the NYSE Official Closing Prices for the five trading days immediately preceding the signing of the binding agreement to issue the securities.

    [4] See Section 312.05 of the NYSE Manual and Nasdaq Marketplace Rule 5635(f).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ele Klein

    Partner

    New York – 919 Third Avenue

    More insights

  • SEC Proposes Limited Exemption for Finders

    SEC Proposes Limited Exemption for Finders

    ARTICLE / CLIENT ALERT

    SEC Proposes Limited Exemption for Finders

    October 9, 2020

    Read time: 5 min

    Key takeaways
    Overview

    On Oct. 7, 2020, the SEC, by a 3-2 vote, proposed a conditional exemption from the broker-dealer registration requirements of Section 15(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), for natural persons who assist issuers with raising capital in private markets from “accredited investors” (“Proposal”). The Proposal provides long-sought guidance regarding payment of transaction-based compensation to unregistered persons, commonly referred to as “finders,” who engage in limited securities-related activities to raise funds on behalf of issuers.

    The Proposal creates two classes of finders, based on the types of activities in which they are permitted to engage, that would qualify for an exemption from registration. A Tier I finder would be permitted to provide a list of potential investors in connection with a single capital raising transaction by a single issuer once every 12 months. Tier I finders may not communicate with investors regarding an investment opportunity. A Tier II finder would be permitted to solicit investors on behalf of an issuer, distribute offering materials to investors, discuss issuer information included in offering materials and participate in meetings with the issuer and investors. Both Tiers of finders would be permitted to receive transaction-based compensation, which has traditionally been considered a hallmark of brokerage activity.

    Under the Proposal, both tiers of finders would have a non-exclusive safe harbor from broker registration provided that the finder’s activities are limited as described below. Importantly, while the Proposal allows finders to receive transaction-based compensation, it does not permit finders to engage in other brokerage-related activities relating to distributions such as: (1) structuring the transaction; (2) negotiating the terms of an offering; (3) participating in the preparation of sales materials; and (4) providing advice regarding the valuation or financial advisability of the investment. Should a finder participate in any of these activities, the Commission notes that the finder may need to analyze whether it has implicated the registration requirements of Section 15 of the Exchange Act.

    The proposed exemptions under both tiers would only be available when: (1) the issuer is seeking to conduct the securities offering in reliance on an applicable exemption from registration under the Exchange Act and is not required to file reports under Section 13 or Section 15(d) of the Exchange Act; (2) the potential investor is an “accredited investor” or the finder has a reasonable belief that the potential investor is an “accredited investor,” as defined in Rule 501 of Regulation D; and (3) the Finder is not an associated person of a broker-dealer or subject to statutory disqualification at the time of his or her participation[1], provides services pursuant to a written agreement[2] with the issuer and does not engage in general solicitation.

    In the Proposal, the Commission discusses the important role of finders in capital formation and the need for such an exemption for small businesses that must raise capital, but not in amounts sufficient to attract either venture capitalists or the assistance of a registered broker-dealer. (The Commission identifies these businesses as those needing to raise less than $5 million.) We note, however, that despite the targeted nature of the identified need, the Proposal does not appear to be similarly targeted. While the proposed exemption is limited to accredited investors and private transactions, there was no discussion in the Proposal regarding an overall cap on funds raised, leaving the door open for larger issuers to avail themselves of the services of a finder that receives transaction-based compensation.

    The Commission also solicits comment on a number of topics in the Proposal. Notably, the Commission seeks comment on a number of topics relating to private fund managers. Specifically, in question 30, the Commission asks whether the proposed exemption should “provide guidance regarding activities of private fund advisers[.]” In question 36, the Commission asks whether the proposed exemption should “be limited to individuals who are not associated persons of a municipal advisor or investment adviser representative of an investment adviser.” The Commission also solicits comment regarding potential alignment of the disclosure requirements for Tier II finders and Rule 206(4)-3 of the Investment Advisers Act (“Cash Solicitation Rule”).

    Finally, we note that because this relief would be issued in the form of an exemptive order rather than a rule, the Commission is not required to follow its formal rulemaking procedure in issuing this relief. Specifically, the Commission is not required to perform any economic analysis of the impact of the exemption or consider its impact on capital formation. Relatedly, because the Commission is not required to follow its formal rulemaking procedure, action on this proposal may occur more quickly.

    Comments on the Proposal are due 30 days after publication in the Federal Register. If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.

    Authored by Brian T. Daly, Marc E. Elovitz, Craig S. Warkol, former Schulte lawyer David Sieradzki and Jacqueline Srour.


    [1] Statutory disqualification is defined in Section 3(a)(39) of the Exchange Act.

    [2] Such written agreement must include a description of the services provided and associated compensation.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    More insights

  • No-Poach Agreements Can Pose Antitrust Risks; Consider Alternatives

    ARTICLE

    No-Poach Agreements Can Pose Antitrust Risks; Consider Alternatives

    October 8, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Raymond A. Jacobsen , Jr.

    Partner

    Washington, DC

    More insights

  • Subpart F Losses

    ARTICLE

    Subpart F Losses

    October 2020

    Read time: 2 min

    Key takeaways
    Overview

    This article is reprinted with the publisher’s permission from International Tax Journal, a bimonthly journal published by
    CCH Incorporated.

    In depth
    Authors

    Lowell D. Yoder

    Partner

    Chicago

    More insights

  • No-Poach Agreements Can Pose Antitrust Risks; Consider Alternatives

    ARTICLE

    No-Poach Agreements Can Pose Antitrust Risks; Consider Alternatives

    October 8, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Raymond A. Jacobsen , Jr.

    Partner

    Washington, DC

    More insights

  • Latin America’s New Investment Landscape

    Latin America’s New Investment Landscape

    ARTICLE

    Latin America’s New Investment Landscape

    October 2020

    Read time: 1 min

    Key takeaways
    Overview

     

     

    In depth
    Authors

    Michael Silva

    Partner

    Miami

    Gregory Weigand

    Counsel

    Miami, New York – One Vanderbilt Avenue

    More insights

  • CCPA Amendment Update: California Governor Approves CCPA Amendment with Exceptions for HIPAA De-Identified Information and Other Health Data

    CCPA Amendment Update: California Governor Approves CCPA Amendment with Exceptions for HIPAA De-Identified Information and Other Health Data

    ARTICLE / CLIENT ALERT

    CCPA Amendment Update: California Governor Approves CCPA Amendment with Exceptions for HIPAA De-Identified Information and Other Health Data

    October 8, 2020

    Read time: 8 min

    Key takeaways
    Overview

    Originally published September 18, 2020. Updated on October 8, 2020.

    On September 25, 2020, California Governor Gavin Newsom signed into law California AB 713, which amends the California Consumer Privacy Act (CCPA) to except from its requirements certain health information, including information that has been de-identified in accordance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). The bill’s enactment eases some of the CCPA compliance challenges experienced by the health care and life sciences industries by more closely aligning the CCPA with HIPAA and other laws governing human subjects research.

    In depth

    On September 25, 2020, Governor Gavin Newsom signed into law California AB 713, which amends the California Consumer Privacy Act (CCPA) to create expanded exceptions for: HIPAA business associates; information that has been de-identified in accordance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and information collected, used or disclosed in certain human subjects research. AB 713 reflects an intense lobbying effort by medical technology, pharmaceutical, and other health and life sciences industry stakeholders. AB 713 became effective immediately following Governor Newsom’s signature, as the bill included an urgency clause calling for immediate action to mitigate the CCPA’s potential negative impact on health-related research.

    AB 713 eases some of the CCPA compliance challenges experienced by the health care and life sciences industries by more closely aligning the CCPA with HIPAA and other laws governing human subjects research. However, AB 713 also creates new compliance obligations by requiring entities subject to requirements for “businesses” under the CCPA, as well as other entities residing or doing business in California, to include certain provisions in license agreements or other contracts for the sale or license of de-identified patient information. While AB 713 becomes effective immediately, as discussed below, it requires compliance with the new contracting requirement beginning January 1, 2021.

    We summarize below the salient provisions of AB 713.

    Exception for De-identified Patient Information

    AB 713 provides relief to health care, life sciences and other organizations that have been grappling with how to achieve compliance with the previously inconsistent de-identification standards under HIPAA and the CCPA. Without AB713’s CCPA amendment, it was possible for data that has been de-identified under the HIPAA de-identification standard to constitute “personal information” under the CCPA because CCPA and the HIPAA Privacy Rule include different language for their respective de-identification standards. This has complicated CCPA-regulated businesses’ strategies for licensing or otherwise commercializing HIPAA de-identified data. For example, HIPAA protected health information that has been de-identified under HIPAA may still contain identifiers of California physicians or other individuals who serve patients. These identifiers may have constituted “personal information” under the CCPA when held by a CCPA-regulated business, creating a right under the CCPA for the individuals to opt out of sales of the personal information. For more information about the inconsistent HIPAA and CCPA de-identification standards, see our On the Subject.

    AB 713 resolves the potential disconnect between the CCPA and HIPAA’s de-identification standards by expressly providing that the CCPA does not apply to information that meets the following conditions:

    • The information has been de-identified in accordance with a HIPAA de-identification method (i.e., the safe harbor or expert determination method).
    • The information was derived from patient information that was originally collected, created, transmitted or maintained by an entity subject to HIPAA, the California Confidentiality of Medical Information Act (CMIA) or the Federal Policy for the Protection of Human Subjects (Common Rule). “Patient information” means protected health information or individually identifiable health information under HIPAA, identifiable private information under the Common Rule or medical information under the CMIA.
    • The information has not been re-identified.

    This exception applies to HIPAA de-identified data held by entities that are not themselves directly regulated by HIPAA, the Common Rule or the CMIA, such as certain pharmaceutical, medical device or life sciences companies, provided that the de-identified data is derived from patient information that was originally collected, created, transmitted or maintained by an entity regulated by HIPAA, the CMIA or the Common Rule.

    Prohibition Against Re-Identification of De-identified Patient Information

    AB 713 also prohibits a CCPA-regulated business or other person from re-identifying, or attempting to re-identify, any de-identified patient information unless the re-identification activity is for one of the following purposes:

    • A HIPAA-regulated entity’s treatment, payment or health care operations purposes
    • Public health activities or purposes set forth in HIPAA
    • Research, as defined by HIPAA and carried out in accordance with the Common Rule
    • Performance of a contract that engages an entity to re-identify the de-identified patient information for testing, analysis or validation of the de-identification
    • Compliance with legal requirements.

    Thus, CCPA-regulated businesses and other persons that seek to re-identify any de-identified patient information need to evaluate whether the CCPA applies to it and permits the re-identification.

    New Contracting Requirements

    Beginning January 1, 2021, AB 713 requires a contract for the sale or license of de-identified patient information, where one of the parties resides or does business in California, to include the following provisions:

    • A statement that the de-identified information being sold or licensed includes de-identified patient information
    • A statement that the CCPA prohibits the purchaser or licensee from re-identifying, or attempting to re-identify, the de-identified patient information
    • A statement that prohibits the purchaser or licensee from further disclosing the de-identified information to any third party unless the third party is contractually bound by the same or stricter restrictions and conditions.

    While the CCPA generally only applies to “businesses” that process the personal information of California consumers and have an annual revenue of at least $25 million (or meet another threshold), the new contracting requirements under AB 713 also apply where “one of the parties is a person residing or doing business in” California even if the business is not based in California. To learn more about whether a company is a CCPA-regulated business, see “Your Guide to CCPA Compliance.”

    Accordingly, beginning January 1, 2021, a party entering into a contract involving the sale or license of de-identified patient information that resides or does business in California should assess whether the contract must include the provisions required by AB 713. Purchasers or licensees of de-identified patient information from an entity that resides or does business in California should evaluate whether they can comply with the contract provisions and flow down the restrictions on re-identification to third parties with whom they further share the de-identified patient information. An open question is whether AB 713 requires contracts entered into prior to January 1, 2021 to be amended to include the contract provisions by such date or at any date of renewal or amendment after such date.

    Expanded Consumer Privacy Notice Requirements

    Although AB 713 excepts de-identified patient information from the CCPA’s applicability, it requires a CCPA-regulated business that sells or discloses de-identified patient information to include in its CCPA consumer privacy notice a statement describing the sale or disclosure and the HIPAA de-identification method used to de-identify the information (i.e., safe harbor or expert determination). Companies that sell, license or transfer HIPAA de-identified data to third parties should consider whether they will need to update their CCPA consumer privacy notices to comply with this requirement.

    Exception for HIPAA Business Associates

    Before AB 713 took effect, the CCPA excepted from its applicability any protected health information collected by a HIPAA covered entity or business associate. The CCPA also contained an exception for all HIPAA covered entities to the extent that they maintain, use or disclose patient information in the same manner as protected health information subject to HIPAA. However, the CCPA did not include a similar entity-based exception for HIPAA business associates and the patient information they protect in the same manner as protected health information.

    AB 713 amends the CCPA to except all business associates to the extent that they maintain, use or disclose patient information in the same manner as protected health information. Accordingly, a CCPA-regulated business associate that collects patient information through a service line that is not subject to HIPAA, such as a direct-to-consumer offering, does not need to comply with the CCPA with respect to such information if the business associate applies HIPAA protections to the information.

    Research Exception

    The CCPA previously included an exception for personal information collected as part of clinical trials that are subject to the Common Rule, international good clinical practice guidelines, or the human subject protection regulations of the US Food and Drug Administration (FDA). AB 713 expands the exception to except any personal information collected, used or disclosed in any research (as defined by HIPAA) that is carried out in accordance with applicable ethics, confidentiality, privacy and security rules of 45 CFR Part 164 (e.g., the HIPAA Privacy and Security Rules), the Common Rule, good clinical practice guidelines issued by the International Council for Harmonisation or FDA human subject protection requirements. Thus, now, the CCPA’s research exception is no longer limited to clinical trials.

    Next Steps

    In light of AB 713’s enactment, entities that license or otherwise disclose de-identified patient information, and licensees and purchasers of the information, should

    • Assess whether their contracts covering the information must include the newly required contract provisions and, if so, revise the contracts,
    • Revise their consumer privacy notices as needed to comply with the new de-identification disclosure requirement and
    • Consider updating their de-identification policies and procedures to reflect the new flexibility created by AB 713.

    For assistance with these steps, contact your regular McDermott lawyer or either of the authors.

    Authors

    Daniel F. Gottlieb

    Partner

    Chicago

    More insights

  • CMS Clarifies Emergency Preparedness Testing Exercise Requirements

    ARTICLE / CLIENT ALERT

    CMS Clarifies Emergency Preparedness Testing Exercise Requirements

    October 7, 2020

    Read time: 4 min

    Key takeaways
    Overview

    On September 28, 2020, the Centers for Medicare and Medicaid Services (CMS) issued a Quality, Safety and Oversight Group memorandum (QSO-20-41-ALL) (the QSO Memo) reinforcing and clarifying the testing exercises required by CMS’s emergency preparedness rule and the exemption that is available to facilities that activated their emergency plans in response to the COVID-19 national public health emergency (PHE). Healthcare facilities should ensure their ability to comply with the testing requirements once the PHE has abated.

    In depth

    On September 8, 2016, CMS published the Emergency Preparedness Requirements for Medicare and Medicaid Participating Providers and Suppliers Final Rule (the Final Rule), later revised in September 2019, which establishes national emergency preparedness requirements to ensure adequate planning for natural and man-made disasters, and coordination with federal, state, tribal, regional and local emergency preparedness systems.

    In part, the Final Rule requires providers and suppliers to perform annual testing exercises to prepare for natural or man-made disasters. Testing exercises required under the Final Rule are divided into two categories: 1) full-scale, functional and individual-facility-based exercises as the “Required Exercises” and 2) mock disaster drills, table-top exercises or workshops as the “Exercises of Choice.” Inpatient providers are required to conduct an Exercise of Choice annually, whereas outpatient providers are required to conduct a Required Exercise every two years with an Exercise of Choice conducted during the intervening years. However, if a provider or supplier experiences a natural or man-made emergency that requires activation of their emergency plan, inpatient and outpatient providers and suppliers will be exempt from their next required testing exercise following the beginning of the emergency event.

    The recent COVID-19 PHE has led many facilities to utilize their emergency plans, which triggers the exemption to the testing exercise requirement under the Final Rule. Providers and suppliers that activated their emergency plan will need to document that they activated their program due to the emergency to utilize this option. While currently exempt from performing testing exercises, facilities must resume annual testing exercises following the COVID-19 PHE. Facilities that are due for an Exercise of Choice will be able to assess the facility’s response to the COVID-19 pandemic and revise their emergency plans accordingly.

    The QSO Memo also provides suggestions as to how to best utilize the testing exercises to improve facilities’ current emergency plans, including a worksheet that illustrates relevant scenarios for providers and suppliers to utilize while conducting their testing exercises once the PHE concludes.

    Key Takeaways
    Providers and suppliers that activated their emergency plans in response to the COVID-19 PHE are exempt from the testing exercise requirement pursuant to the Final Rule. However, these providers will need to prepare to conduct their next required testing exercise following the conclusion of the PHE. Providers will be able to take advantage of the testing exercise to assess their facilities’ responses to the PHE and revise their emergency plans for any shortcomings found throughout this PHE and the subsequent testing exercises.

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    More insights

  • Recent Development in Tax Law: Tax Issues Relating to Cross-Border Unsecured Group Loans

    ARTICLE

    Recent Development in Tax Law: Tax Issues Relating to Cross-Border Unsecured Group Loans

    October 2020

    Read time: 2 min

    Key takeaways
    Overview

    Dr. Gero Burwitz authored the article “Recent Development in Tax Law: Tax Issues Relating to Cross-Border Unsecured Group Loans”, featured in Neue Zeitschrift für Gesellschaftsrecht (NZG), p. 1099-1101 in October, 2020.

    In depth
    Authors

    Dr. Gero Burwitz

    Partner

    Munich

    More insights